Emerging retatrutide, a dual -action drug targeting both GLP-1 and GIP receptors, is creating considerable excitement within the medical community. Initial clinical research have demonstrated substantial reductions in physical mass and improvements in metabolic markers for people with overweight. Scientists believe this ground-breaking approach has